If you could only do one thing to improve the health of children in the U.S., it would have to be in the behavioral health sphere, Nemours Children's Health CEO Lawrence Moss declared at HLTH. The state of youth mental health has reached a crisis point in the U.S., and Moss' health system is working hard to address this. Some of its efforts include embedding behavioral health into primary care and deploying behavioral health workers in schools.
Pfizer’s new FDA-approved ulcerative colitis drug Velsipity comes from its $6.7 billion Arena Pharmaceuticals acquisition. The small molecule will compete against blockbuster Bristol Myers Squibb drug Zeposia, which addresses the same target.
At HLTH, General Catalyst Principal Candace Richardson discussed some of the questions she frequently asks startups during investment meetings. Some of these include "Do you stratify your outcomes data by different populations to ensure your model works well for everyone?" and "Is serving Medicaid populations on your roadmap?"
Cancer and pharmacy services are driving up costs for employers. One Mercer exec recently laid out several recommendations for employers to manage these costs.
BioNTech gains rights to a MediLink Therapeutics antibody drug conjugate that targets tumors expressing the HER3 protein. The deal comes six months after the German company entered the ADC field by acquiring rights to two therapeutic candidates from DualityBio.